Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression

Exclusion Criteria

• •With morphologic evidence of clonal evolution (patients with isolated bone marrow cytogenetic abnormalities are also eligible excepted chromosome 7 abnormalities and complex karyotype)
• •With uncontrolled infection
• •With seropositivity for HIV or HTLV-1 (Human T cell Leukemia) or active hepatitis B or C defined by a positive PCR (polymerase chain reaction) HBV (hepatitis B virus) or HCV (hepatitis C virus) and associated hepatic cytolysis
• •Cancer in the last 5 years (except basal cell carcinoma of the skin or "in situ" carcinoma of the cervix)
• •Pregnant (βHCG positive) or breast-feeding.
• •Who received live attenuated vaccine within 2 months before transplantation and during the research
• •Uncontrolled coronary insufficiency, recent myocardial infarction \<6 month, current manifestations of heart failure, uncontrolled cardiac rhythm disorders, ventricular ejection fraction \<50%
• •With heart failure according to NYHA (New York Heart Association) (II or more)
• •Preexisting acute hemorrhagic cystitis
• •Renal failure with creatinine clearance \<30ml / min
• •With urinary tract obstruction
• •Who receive the following treatments Phenytoin, Pentostatin, inhibitor of adenoside)
• •Who have any debilitating medical or psychiatric illness, which preclude understanding the inform consent as well as optimal treatment and follow-up
• •Under tutorship or curatorship